These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

923 related articles for article (PubMed ID: 26457691)

  • 1. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
    Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
    J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.
    de Meel RHP; Tannemaat MR; Verschuuren JJGM
    Neuromuscul Disord; 2019 Sep; 29(9):664-670. PubMed ID: 31488385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
    Kupersmith MJ; Ying G
    Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
    Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
    Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.
    Zach H; Cetin H; Hilger E; Paul A; Wuschitz B; Jung R; Auff E; Zimprich F
    Eur J Neurol; 2013 Apr; 20(4):708-13. PubMed ID: 23279780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual case of recurrent falls: myasthenia gravis in an elderly patient.
    Alaama T; Basharat P; Nicolle MW
    Can Fam Physician; 2012 Nov; 58(11):1231-2. PubMed ID: 23152461
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to treatment in pediatric ocular myasthenia gravis.
    Xu L; Castro D; Reisch JS; Iannaccone ST
    Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dropped head as an unusual presenting sign of myasthenia gravis.
    D'Amelio M; Di Benedetto N; Ragonese P; Daniele O; Brighina F; Fierro B; Savettieri G
    Neurol Sci; 2007 Apr; 28(2):104-6. PubMed ID: 17464475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
    de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
    Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of double seronegative ocular myasthenia gravis.
    Goto T; Kimura A; Masuda A; Mochizuki Y; Gomi F
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; 262(8):2617-2623. PubMed ID: 38416235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
    Mullaney P; Vajsar J; Smith R; Buncic JR
    Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic yields and clinical features of ocular myasthenia gravis.
    Kim H; Oh SY
    Medicine (Baltimore); 2021 Jun; 100(25):e26457. PubMed ID: 34160444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis in Jamaican children: a 12-year institutional review.
    Melbourne Chambers R; Forrester S; Gray R; Tapper J; Trotman H
    Paediatr Int Child Health; 2012 Feb; 32(1):47-50. PubMed ID: 22525448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
    Vissing J; O'Brien F; Wang JJ; Howard JF
    Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.